In vitro and in vivo performance of a dual drug-eluting stent (DDES)

Biomaterials

Volumn 31, Issue 15, 2010, Pages 4382-4391

  Huang, Yingying ^a   Venkatraman Subbu S , S S ^a   Boey, Freddy Y C ^a   Lahti, Eeva M ^b   Umashankar, P R ^c   Mohanty, Mira ^c   Arumugam, Sabareeswaran ^c   Khanolkar, Laxmikant ^d   Vaishnav, Sudhir ^e  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c SREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES AND TECHNOLOGY   (India)

^d Insightra Medical Inc   (United States)

^e Asian Heart Institute   (India)

Author keywords

Cobalt alloy; Drug release; Restenosis; Stent; Thrombosis

Indexed keywords

ANTI-PROLIFERATIVE; BEFORE AND AFTER; CAROTID ARTERY; CORONARY ARTERY DISEASE; DRUG RELEASE; DRUG-ELUTING STENTS; IN-VITRO; IN-VIVO; PLATELET ADHESION; PURE POLYMERS; RESTENOSIS; SIROLIMUS; SPRAY COATING; THROMBUS FORMATION;

ARTIFICIAL ORGANS; BIODEGRADABLE POLYMERS; BIODEGRADATION; BLOOD SUBSTITUTES; CHROMIUM; COBALT; COBALT ALLOYS; PATHOLOGY; PLASTIC COATINGS; PLATELETS; SURFACE PROPERTIES;

DISEASES;

CHROMIUM; COBALT; POLYMER; RAPAMYCIN; TRIFLUSAL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BARE METAL STENT; CAROTID ARTERY; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; DRUG RELEASE; DUAL DRUG ELUTING STENT; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MATERIAL COATING; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; SURFACE PROPERTY; SWINE; THROMBOCYTE ADHESION; THROMBOGENESIS; THROMBOSIS;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; COATED MATERIALS, BIOCOMPATIBLE; DRUG DELIVERY SYSTEMS; DRUG-ELUTING STENTS; HUMANS; HYPERPLASIA; MATERIALS TESTING; PLATELET ADHESIVENESS; PLATELET AGGREGATION INHIBITORS; SALICYLATES; SIROLIMUS; SURFACE PROPERTIES; SWINE; THROMBOSIS;

SUS;

EID: 77949653594     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.01.147     Document Type: Article

References (40)

1. Kivelä A., Hartikainen J. Restenosis related to percutaneous coronary intervention has been solved?. Ann Med 2006, 38:173-187.
2. Tsuchida K., Serruys P.W., Bruining N., Dudek D., Drzewiecki J., Banning A.P., et al. Two-year serial coronary angiographic and intravascular ultrasound analysis of in-stent angiographic late lumen loss and ultrasonic neointimal volume from the TAXUS II trial. Am J Cardiol 2007, 99:607-615.
3. Degertekin M., Serruys P.W., Foley D.P., Tanabe K., Regar E., Vos J., et al. Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. Circulation 2002, 106:1610-1613.
4. Venkatraman S., Boey F. Release profiles in drug-eluting stents: issues and uncertainties. J Control Release 2007, 120:149-160.
5. Bavry A.A., Bhatt D.L. Appropriate use of drug-eluting stents: balancing the reduction in restenosis with the concern of bate thrombosis. Lancet 2008, 371:2134-2143.
6. Tsimikas S. Drug-eluting stents and late adverse clinical outcomes lessons learned, lessons awaited. J Am Coll Cardiol 2006, 47:2112-2115.
7. Colombo A., Drzewiecki J., Banning A., Grube E., Hauptmann K., Silber S., et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003, 108:788-794.
8. Schwartz R.S., Chronos N.A., Virmani R. Preclinical restenosis models and drug-eluting stents: still important, still much to learn. J Am Coll Cardiol 2004, 44:1373-1385.
9. Gautam Kedia M.S.L. Stent thrombosis with drug-eluting stents: a re-examination of the evidence. Catheter Cardiovasc Interv 2007, 69:782-789.
10. Ong A.T.L., Hoye A., Aoki J., van Mieghem C.A.G., Granillo G.A.R., Sonnenschein K., et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005, 45:947-953.
11. Richter G.M., Palmaz J.C., Noeldge G., Tio F. Relationship between blood flow, thrombus, and neointima in stents. J Vasc Interv Radiol 1999, 10:598-604.
12. Mehran R., Aymong E.D., Ashby D.T., Fischell T., Whitworth H., Siegel R., et al. Safety of an aspirin-alone regimen after intracoronary stenting with a heparin-coated stent: final results of the HOPE (HEPACOAT and an antithrombotic regimen of aspirin alone) study. Circulation 2003, 108:1078-1083.
13. Whelan D.M., van der Giessen W.J., Krabbendam S.C., van Vliet E.A., Verdouw P.D., Serruys P.W., et al. Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries. Heart 2000, 83:338-345.
14. Lee Y.-K., Hyung Park J., Tae Moon H., Yun Lee D., Han Yun J., Byun Y. The short-term effects on restenosis and thrombosis of echinomycin-eluting stents topcoated with a hydrophobic heparin-containing polymer. Biomaterials 2007, 28:1523-1530.
15. Venkatraman S, Boey F and Khanolkar L. A non-biodegradable stent comprising a biodegradable coating and a method of coating the same. PCT Patent Application No. PCT/SG2008/000413, 2007.
16. Cho H.-Y., Jeong T.-J., Lee Y.-B. Simultaneous determination of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in rat and human plasma by high-performance liquid chromatography. J Chromatogr B 2003, 798:257-264.
17. Rodríguez G., Gallardo A., Fernández M., Rebuelta M., Buján J., Bellón J.M., et al. Hydrophilic polymer drug from a derivative of salicylic acid: synthesis, controlled release studies and biological behavior. Macromol Biosci 2004, 4:579-586.
18. Peppas N.A., Huang Y., Torres-Lugo M., Ward J.H., Zhang J. Physicochemical foundations and structural design of hydrogels in medicine and biology. Annu Rev Biomed Eng 2000, 2:9-29.
19. Jain R.A. The manufacturing techniques of various drug loaded biodegradable poly (lactide-co-glycolide) (PLGA) devices. Biomaterials 2000, 21:2475-2490.
20. Vert M., Suming L., Garreau H. More about the degradation of LA/GA-derived matrices in aqueous media. J Control Release 1991, 16:15-26.
21. Huang Y., Venkatraman S.S., Boey F.Y.C., Umashankar P.R., Mohanty M., Arumugam S. The short-term effect on restenosis and thrombosis of a cobalt-chromium stent eluting two drugs in a porcine coronary artery model. J Interv Cardiol 2009, 22:466-478.
22. Schwartz R.S., Huber K.C., Murphy J.G., Edwards W.D., Camrud A.R., Vlietstra R.E., et al. Restenosis and the proportional neointimal response to coronary-artery injury - results in a porcine model. J Am Coll Cardiol 1992, 19:267-274.
23. Schwartz R.S., Edelman E.R., Carter A., Chronos N., Rogers C., Robinson K.A., et al. Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation 2002, 106:1867-1873.
24. Frank A., Rath S.K., Venkatraman S.S. Controlled release from bioerodible polymers: effect of drug type and polymer composition. J Control Release 2005, 102:333-344.
25. Schulz C., Herrmann R.A., Beilharz C., Pasquantonio J., Alt E. Coronary stent symmetry and vascular injury determine experimental restenosis. Heart 2000, 83:462-467.
26. Sullivan T.M., Ainsworth S.D., Langan E.M., Taylor S., Snyder B., Cull D., et al. Effect of endovascular stent strut geometry on vascular injury, myointimal hyperplasia, and restenosis. J Vasc Surg 2002, 36:143-149.
27. Celik T., Iyisoy A., Barindik N., Isik E. Glucocorticoids in the prevention of in-stent restenosis: the role of inflammation. Int J Cardiol 2009, 135:403-405.
28. Kim J.Y., Ko Y.G., Shim C.Y., Park S., Hwang K.C., Choi D., et al. Comparison of effects of drug-eluting stents versus bare metal stents on plasma C-reactive protein levels. Am J Cardiol 2005, 96:1384-1388.
29. Rogers C., Welt F.G.P., Karnovsky M.J., Edelman E.R. Monocyte recruitment and neointimal hyperplasia in rabbits. Coupled inhibitory effects of heparin. Arterioscler Thromb Vasc Biol 1996, 16:1312-1318.
30. Welt F.G.P., Edelman E.R., Simon D.I., Rogers C. Neutrophil, not macrophage, infiltration precedes neointimal thickening in balloon-injured arteries. Arterioscler Thromb Vasc Biol 2000, 20:2553-2558.
31. Suzuki T., Kopia G., Hayashi S., Bailey L.R., Llanos G., Wilensky R., et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001, 104:1188-1193.
32. Nakazawa G., Finn A.V., John M.C., Kolodgie F.D., Virmani R. The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents. Am J Cardiol 2007, 100:36M-44M.
33. Kereiakes D.J., Cox D.A., Hermiller J.B., Midei M.G., Bachinsky W.B., Nukta E.D., et al. Usefulness of a cobalt chromium coronary stent alloy. Am J Cardiol 2003, 92:463-466.
34. Hong M.K., Kornowski R., Bramwell O., Ragheb A.O., Leon M.B. Paclitaxel-coated Gianturco-Roubin II (GR II) stents reduce neointimal hyperplasia in a porcine coronary in-stent restenosis model. Coron Artery Dis 2001, 12:513-515.
35. Jabara R., Ollerenshaw J., Chronos N., Tondato F., Conway D., Molema W., et al. Toxic vessel reaction to an absorbable polymer-based paclitaxel-eluting stent in pig coronary arteries. J Invasive Cardiol 2006, 18:383-390.
36. Grube E., Sonoda S., Ikeno F., Honda Y., Kar S., Chan C., et al. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation 2004, 109:2168-2171.
37. Carter A.J., Brodeur A., Collingwood R., Ross S., Gibson L., Wang C.A., et al. Experimental efficacy of an everolimus eluting cobalt chromium stent. Catheter and Cardiovasc Interv 2006, 68:97-103.
38. Lowe H.C., Chesterman C.N., Khachigian L.M. Does thrombus contribute to in-stent restenosis in the porcine coronary stent model?. Thromb Haemost 2001, 85:1117-1118.
39. Rodriguez G., Gallardo A., San Roman J., Rebuelta M., Bermejo P., Bujan J., et al. New resorbable polymeric systems with antithrombogenic activity. J Mater Sci Mater Med 1999, 10:873-878.
40. Garasic J., Edelman E., Rogers C. Stent design and the biologic response. Frontiers in interventional cardiology 1997, 95-100. Martin Dunitz Ltd, London. R. Beyar, G. Keren, M. Leon (Eds.).